actin-binding motif comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
On 16 December 1944, the Germans launched a surprise offensive through the Ardennes Forest, which became known as the Battle of the Bulge. In SHAEF reserve, the 82nd was committed on the northern face of the bulge near Elsenborn Ridge. On 20 December 1944, the 82nd Airborne Division was assigned to take Cheneux which had been captured by Kampfgruppe Peiper. On 21–22 December 1944, the 82nd Airborne faced counterattacks from two Waffen SS divisions which included the 1st SS Panzer Division Leibstandarte SS Adolf Hitler (lit. translation "The SS Bodyguard Division of Adolf Hitler") and the 9th SS Panzer Division Hohenstaufen. The Waffen SS efforts to relieve the Kampfgruppe Peiper failed due to the stubborn defense of the 82nd Airborne, the 30th ID, 2nd ID, and other units. On December 23, German forces launched an attack from the south, overrunning elements of the 325th Glider Infantry Regiment at the Baraque-Fraiture crossroads. This maneuver compromised the southern flank of the 82nd Airborne Division. The objective of the 2nd SS Panzer Division Das Reich was to outflank the 82nd Airborne Division rather than to directly link up with the isolated Kampfgruppe Peiper further north. However, a successful encirclement could have opened a corridor to reach the cut-off armored unit. The German offensive failed to achieve this breakthrough before American reinforcements stabilized the perimeter.
=== Genetics === The sequencing of a full cephalopod genome has remained challenging to researchers due to the length and repetition of their DNA. The characteristics of cephalopod genomes were initially hypothesized to be the result of entire genome duplications. Following the full sequencing of a California two-spot octopus, the genome showed similar patterns to other marine invertebrates with significant additions to the genome assumed to be unique to cephalopods. No evidence of full genome duplication was found. Within the California two-spot octopus genome there are substantial replications of two gene families. Significantly, the expanded gene families were only previously known to exhibit replicative behaviour within vertebrates. The first gene family was identified as the protocadherins which are attributed to neuron development. Protocadherins function as cell adhesion molecules, essential for synaptic specificity. The mechanism for protocadherin gene family replication in vertebrates is attributed to complex splicing, or cutting and pasting, from a locus. Following the sequencing of the California two-spot octopus, researchers found that the protocadherin gene family in cephalopods has expanded in the genome due to tandem gene duplication. The different replication mechanisms for protocadherin genes indicate an independent evolution of protocadherin gene expansion in vertebrates and invertebrates. Analysis of individual cephalopod protocadherin genes indicate independent evolution between species of cephalopod.
Dissociation of the target mRNA strand from RISC after the cleavage allows more mRNA to be silenced; this dissociation process is likely to be promoted by extrinsic factors driven by ATP hydrolysis. Sometimes, cleavage of the target mRNA molecule does not occur. In some cases, the endonucleolytic cleavage of the phosphodiester backbone may be suppressed by mismatches of siRNA and target mRNA near the cleaving site. Other times, the Argonaute proteins of the RISC lack endonuclease activity even when the target mRNA and siRNA are perfectly paired. In such cases, gene expression will be silenced by an miRNA-induced mechanism instead.
Sources: en.wikipedia.org
=== Relation of PIDD1 to centrosomes === Recent investigations reveal that CASP2 activation, which is dependent on PIDD1, does not lead to cell death or activate p53 in reaction to DNA damage (such as that induced by doxorubicin) or during prolonged mitotic arrest (as observed with taxol treatment). In contrast, the p53 activation linked to centrosome amplification—a process that can occur following failed cytokinesis—undoubtedly depends on the Caspase-2−PIDDosome complex. Notably, PIDD1 appears to be integral in assessing the quantity of mature mother centrioles, utilizing a mechanism that has yet to be fully clarified. Furthermore, PIDD1 is situated at the distal ends of mature centrosomes within normal cells, suggesting its potential role in regulating centrosomal functions. The assembly of the Caspase-2−PIDDosome can be triggered by the presence of multiple mature centrioles with appendages. This activation leads to CASP2-mediated cleavage of MDM2, resulting in the accumulation of p53 and subsequent cell cycle arrest mediated by p21. Notably, these processes occur without causing significant cell death. Similarly, the depletion of centrosomes undermines the effectiveness of this pathway during instances of cytokinesis failure. In contrast, overexpressing polo-like kinase 4 (PLK4), which promotes the formation of additional centrosomes, is sufficient to activate the pathway even when cytokinesis is not compromised.
Helene Langevin is an American medical scientist who served as the Director of the National Center for Complementary and Integrative Health (NCCIH) at the National Institutes of Health (NIH) between November 2018 and November 2025. She was a professor in the University of Vermont College of Medicine's Department of Neurological Sciences. She is best known for characterizing certain cellular and mechanical effects of acupuncture. She was also a Professor in Residence of Medicine at Harvard Medical School, Brigham and Women's Hospital. Prior to working at NIH, Langevin was the Director of the Osher Center for Integrative Medicine, jointly owned by Brigham and Women's Hospital and Harvard Medical School. Langevin was the principal investigator of studies funded by the National Institutes of Health. The Boston Globe describes her as a "celebrity" in the world of acupuncture.
=== Pharmacokinetics === Dihydroergocriptine has two main pharmacokinetic advantages over levodopa. The first pharmacokinetic advantage is its half-life of 12 to 16 hours. This relatively long half-life is considered to contribute to the compound's effectiveness in Parkinson's disease, particularly since it allows for more continuous stimulation of brain dopaminergic receptors than short-acting drugs such as levodopa. Though the exact reason is not known, continuous stimulation is considered to reduce risk for motor complications. The second pharmacokinetic advantage is the lack of dietary influence on drug absorption. This characteristic also allows for more sustained dopamine receptor stimulation. DHEC can be taken with a single oral dose and is rapidly absorbed. Peak plasma concentrations occur between 30 and 120 minutes after administration. The strong first-pass hepatic metabolism results in poor bioavailability. Less than 5% of the original dosage reaches the circulation.
==== Medication use ==== Most medications are compatible with continued breastfeeding. Many medicines pass into breastmilk in small amounts; however, very few medications actually reach the infant and are absorbed in a way that would actually impact the infant. Several characteristics of medications, including size and pH of the medication molecule and how well the medication is absorbed in the GI tract, influence how much of a medication may reach, and may ultimately be absorbed, by the infant. In addition to the effects on the infant, many medications are known to significantly suppress milk production, including pseudoephedrine, diuretics, and contraceptives that contain estrogen. There are several resources to assist medical professionals in determining which medications are safe for pregnancy and breastfeeding. While patients can use these resources, they are targeted toward medical professionals. Patients should be encouraged to consult a lactation specialist or a medical provider trained in breastfeeding medicine if any concerns arise. Two helpful resources are listed below.
Sources: en.wikipedia.org
=== Industries and economic zones === Ningxia was a major recipient of China's investment in industrial capacity during the Third Front campaign. Yinchuan Economic and Technological Development Zone was established in 1992. Spanning 32 km2 (12 sq mi), it has an annual economic output Rmb23.7 billion (25.1% up) (US$3.5 billion). Major investors are mainly local enterprises such as Kocel Steel Foundry, FAG Railway Bearing (Ningxia), Ningxia Little Giant Machine Tools, etc. Major industries include machinery and equipment manufacturing, new materials, fine chemicals and the animation industry. Desheng Industrial Park (in Helan County) is a base for about 400 enterprises. The industrial park has industrial chains from Muslim food and commodities to trade and logistics, new materials and bio-pharmaceuticals that has 80 billion yuan in fixed assets. Desheng is looking to be the most promising industrial park in the city. It achieved a total output value of 4.85 billion in 2008, up 40 percent year-on-year. The local government plans to cut taxes and other fees to reduce the burden on local enterprises. The industrial output value reached 2.68 billion yuan in 2008, an increase of 48 percent from a year earlier.
Another aspect of QD toxicity is that there are, in vivo, size-dependent intracellular pathways that concentrate these particles in cellular organelles that are inaccessible by metal ions, which may result in unique patterns of cytotoxicity compared to their constituent metal ions. The reports of QD localization in the cell nucleus present additional modes of toxicity because they may induce DNA mutation, which in turn will propagate through future generation of cells, causing diseases. Although concentration of QDs in certain organelles have been reported in in vivo studies using animal models, no alterations in animal behavior, weight, hematological markers, or organ damage has been found through either histological or biochemical analysis. These findings have led scientists to believe that intracellular dose is the most important determining factor for QD toxicity. Therefore, factors determining the QD endocytosis that determine the effective intracellular concentration, such as QD size, shape, and surface chemistry determine their toxicity. Excretion of QDs through urine in animal models also have demonstrated via injecting radio-labeled ZnS-capped CdSe QDs where the ligand shell was labeled with 99mTc. Though multiple other studies have concluded retention of QDs in cellular levels, exocytosis of QDs is still poorly studied in the literature. While significant research efforts have broadened the understanding of toxicity of QDs, there are large discrepancies in the literature, and questions still remain to be answered.
== Analysis == Quincy Institute's political scientist Annelle Sheline has argued that Trump's plan for Gaza would not only constitute ethnic cleansing, but would also destabilize the Middle East, since the displacement of Palestinians into Jordan would provoke a period of social upheaval that could topple the Jordanian monarchy and create an entirely new state in the region. She argued that if such an event were to take place, the Jordanian Muslim Brotherhood could seize control of the country. This view has been supported by Paul Piller (fellow at the Quincy Institute) who argued that the displacement of Palestinians into Jordan would effectively end the Jordanian-Israeli peace agreement of 1994 and risk the overthrow of the Jordanian monarchy. Oraib Rantawi, head of the Amman Al Quds Center for Political Studies, said the plan would affect Jordan's demography, identity, and security. Egyptian officials warned that the inflow of hundreds of thousands of Hamas militants into the Sinai border resulting from the plan would destabilize the region and put Egypt's peace agreement with Israel in jeopardy. Also at the Quincy Institute, Rabwan Ahari has argued that Trump's proposal signals a clear and substantial departure from America having "even the pretense of supporting a two-state solution." They further argued that this plan amounted to a statement that Palestinian displacement was the goal of US policy surrounding the region.
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
Standard practice is a desiccated container at −20 °C, protected from light and kept sealed between uses. Letting the vial reach room temperature before opening reduces condensation on the powder. Repeated warming and cooling of the whole container is generally avoided.